

Accepted Manuscript

POINT: Will New Anti-eosinophilic Drugs Be Useful In Asthma Management: Yes

Paul M. O'Byrne, MBBCh, FCCP

PII: S0012-3692(16)59339-8

DOI: [10.1016/j.chest.2016.09.021](https://doi.org/10.1016/j.chest.2016.09.021)

Reference: CHEST 706


To appear in: *CHEST*

Received Date: 20 September 2016

Accepted Date: 20 September 2016

Please cite this article as: O'Byrne PM, POINT: Will New Anti-eosinophilic Drugs Be Useful In Asthma Management: Yes, *CHEST* (2016), doi: 10.1016/j.chest.2016.09.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



POINT: Will New Anti-eosinophilic Drugs Be Useful In Asthma Management: Yes

Paul M O'Byrne, MBBCh, FCCP

*Firestone Institute of Respiratory Health and the Department of Medicine,
Michael G DeGroot School of Medicine, McMaster University,
Hamilton, Ontario, Canada.*

Author for correspondence:

Paul M. O'Byrne
Rm 3W10, McMaster University Medical Center
1280 Main Street West, Hamilton,
Ontario, L8S 4K1, Canada
Email: obyryp@mcmaster.ca

POB has held grants-in aid from GSK for the investigation of mepolizumab and Medimmune for the investigation of benralizumab. POB also reports consulting fees from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Medimmune, Merck, Takeda, Abbott, and grants-in-aid from AstraZeneca, Amgen, Genentech, Novartis Axican, Alakos.

Download English Version:

<https://daneshyari.com/en/article/5601040>

Download Persian Version:

<https://daneshyari.com/article/5601040>

[Daneshyari.com](https://daneshyari.com)